Literature DB >> 9770715

[Chest X ray: routine indication in the follow-up of differentiated thyroid cancer?].

J Lorenzen1, M Beese, J Mester, K Brumma, W Beyer, M Clausen.   

Abstract

AIM: This retrospective study sought to elucidate whether routine chest x-ray is still useful for detection of pulmonary metastases in low risk patients despite the high sensitivity of the tumor marker thyroglobulin.
METHOD: The hospital files of 609 patients with well-differentiated thyroid cancer were analysed. Pulmonary formation of metastases was diagnosed in 50 patients. The thyroglobulin value at the time of diagnosis was compared with the chest x-ray findings and, if present, additional diagnostic information such as Iodine-131 whole body scintigraphy (WBS) and thorax CT.
RESULTS: The sensitivity of the chest x-ray to detect pulmonary metastases was at 52% lower than that of WBS (64%), thorax CT (82%) and thyroglobulin during suppression therapy (86%). Among the patients with papillary carcinoma stage I and II (UICC 1987), only 1 patient developed pulmonary metastases during follow up. In this low risk group of patients, detection of lung metastases exclusively by chest x-ray, without elevation of thyroglobulin level is extremely rare (calculated probability 1/4000) and associated with considerable costs.
CONCLUSION: Routine, life long chest x-ray in low risk patients without a suspected recurrence (e.g. positive thyroglobulin) needs to be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770715

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  6 in total

1.  Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan.

Authors:  C Ceccarelli; F Bianchi; D Trippi; F Brozzi; F Di Martino; P Santini; R Elisei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

2.  One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy.

Authors:  Rosália P Padovani; Teresa S Kasamatsu; Claudia C D Nakabashi; Cleber P Camacho; Danielle M Andreoni; Eduardo Z Malouf; Marilia M S Marone; Rui M B Maciel; Rosa Paula M Biscolla
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

3.  Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer.

Authors:  Do-Hoon Kim; Ji-Hoon Jung; Seung Hyun Son; Choon-Young Kim; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2013-10-15

4.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.

Authors:  Bo Youn Cho; Hoon Sung Choi; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; Kyung Won Kim; Ka Hee Yi; June-Key Chung; Yeo-Kyu Youn; Nam Han Cho; Do Joon Park; Chang-Soon Koh
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

5.  Utility of Iodine-131 hybrid SPECT-CT fusion imaging before high-dose radioiodine therapy in papillary thyroid carcinoma.

Authors:  Anish Bhattacharya; Sunil Hejjaji Venkataramarao; Chandra Sekhar Bal; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2010-01

6.  Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma.

Authors:  Seyfettin Ilgan; A Ozgur Karacalioglu; Yuksel Pabuscu; G Kaan Atac; Nuri Arslan; Emel Ozturk; Bengul Gunalp; M Ali Ozguven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.